IP Library Granted Patent US 7,897,743
Granted Patent B2
US 7,897,743 · App. 12/012,028 · Granted Mar 1, 2011

Humanized GM-CSF antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,897,743
App. No.
12/012,028
Granted
Mar 1, 2011
Kind
B2
Abstract

Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as methods for manufacturing these, are also disclosed.

Claims (12)

1. An isolated nucleic acid molecule which encodes a chimerized, GM-CSF specific antibody light chain, the amino acid sequence of which consists of the amino acid encoded by nucleotides 1357-1752 of SEQ ID NO: 35, concatenated to the amino acid sequence encoded by nucleotides 1886-2203 of SEQ ID NO: 35.

2. An isolated nucleic acid molecule which encodes a chimerized, GM-CSF specific antibody heavy chain, the amino acid sequence of which consists of the amino acid encoded by nucleotides 1357-1764 of SEQ ID NO: 36, concatenated to the amino acid sequence encoded by nucleotides 1839-2825 of SEQ ID NO: 36.

3. An expression vector which comprises the isolated nucleic acid molecule of claim 1 , operably linked to a promoter.

4. An expression vector which comprises the isolated nucleic acid molecule of claim 2 , operably linked to a promoter.

5. An expression vector of claim 3 , consisting of the nucleotide sequence of SEQ ID NO: 35.

6. An expression vector of claim 4 , consisting of the nucleotide sequence of SEQ ID NO: 36.

7. A recombinant cell, transformed or transfected with the isolated nucleic acid molecule of claim 1 .

8. A recombinant cell, transformed or transfected with the isolated nucleic acid molecule of claim 2 .

9. The isolated nucleic acid molecule of claim 1 comprising nucleotides 1357-1752 and 1886-2203 of SEQ ID NO: 35.

10. The isolated nucleic acid molecule of claim 2 comprising nucleotides 1357-1764 and 1839-2825 of SEQ ID NO: 36.

11. A recombinant cell transformed or transfected with the expression vector of claim 3 .

12. A recombinant cell transformed or transfected with the expression vector of claim 4 .

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Mar 30, 2018
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: KALOBIOS PHARAMECUTICALS, INC.
Reel/Frame 045788/0148 →
RELEASE OF SECURITY INTEREST Recorded Mar 30, 2018
From: BLACK HORSE CAPITAL MASTER FUND LTD.
To: KALOBIOS PHARAMECUTICALS, INC.
Reel/Frame 045855/0533 →
SECURITY INTEREST Recorded Dec 22, 2016
From: KALOBIOS PHARAMECUTICALS, INC.
To: BLACK HORSE CAPITAL MASTER FUND LTD.
Reel/Frame 041181/0605 →